ArticlePharmaceutical research2026
Triazavirin And Its Derivatives Act As Influenza A Virus Fusion Inhibitors.
Article in Pharmaceutical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeThe influenza A virus still remains one of the most dangerous pathogens possessing a high potential for the emergence of pandemic strains. However, there are only a few antivirals which are still effective against this virus. So-called viral fusion inhibitors are considered as a relatively new class of such drugs with a high therapeutic potential.
methodsWe combined a system for monitoring the fusion of individual virions with lipid membranes, molecular dynamics simulations and measurements of affinity of charged molecules to lipid membranes. This allowed us to determine the mechanism of action of the antiviral drug.
resultsWe demonstrated that the additional mode of activity of triazavirin, the azoloazine derivative, passed clinical trials, can be an inhibition of the hemagglutinin of the influenza A virus. Combining experimental and computer approaches, we report a more effective modification of the target molecule than the registered drug triazavirin. Additionally, we suggested screening system, which has a good potential for studying the fusion activity and its inhibition for other viruses and potential antiviral drugs acting on viral fusion proteins.
conclusionsWe report here triazavirin as a fusion inhibitor and propose a new molecule with high activity against influenza A virus, surpassing those of the triazavirin.
Indexed as
Identifiers
42834254What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.